// App-Quantinova.ai

1306 : Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Researchers

Presenter

  • Jennifer R. Brown

Principal Investigators

  • Paolo Ghia

  • Brad S. Kahl

  • Patricia Walker

  • Wojciech Janowski

  • Henry Chan

  • Mazyar Shadman

  • Peter S. Ganly

  • Luca Laurenti

  • Stephen Opat

  • Monica Tani

  • Hanna Ciepluch

  • Emma Verner

  • Martin imkovic

  • Anders sterborg

  • Marek Trnen

  • Alessandra Tedeschi

  • Piers Blombery

  • Jason C. Paik

  • Fangfang Yin

  • Shibao Feng

  • Vanitha Ramakrishnan

  • Jane Huang

  • Peter Hillmen

  • Constantine S. Tam

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Medical University of Lodz, Lodz, Poland

  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

  • Washington Uni. School of Medicine in St. Louis, Saint Louis, MO.

  • Peninsula Private Hospital, Frankston Victoria, Australia

  • Calvary Mater Newcastle, Waratah, NSW, Australia

  • North Shore Hosp, Auckland, New Zealand

  • Dept of Medicine, Univ of Washington, Seattle, WA

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Department of Haematology, Christchurch Hospital, Christchurch, New Zealand

  • Department of Pathology and Biomedical Science,University of Otago,Christchurch,New Zealand

  • Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy

  • Monash Health, Clayton, Australia

  • Deakin University, Melbourne, Australia

  • Haematology Unit ,Santa Maria delle Croci Hospital,Ravenna,Italia

  • Department of Hematology, Copernicus Regional Oncology Centre, Gdansk, Poland

  • Concord Repatriation General Hospital, Concord, NSW, Australia

  • Department of Clinical Hematology, University Hospital, Hradec Kralove, Czech Republic

  • First Faculty of Medicine, Charles University, Prague, Czech Republic

  • Department of Oncology, Karolinska University Hospital, Stockholm, Sweden

  • Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden

  • Department of Internal Medicine, st Faculty of Medicine, Charles University, Central Military Hospital, Prague, Czech Republic

  • Grande Ospedale Metropolitano Niguarda, Milan, Italy

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc.,San Mateo, CA,Vereinigte Staaten

  • St. James's University Hospital, Leeds, United Kingdom

  • Royal Melbourne Hospital, Parkville, Australia

  • St Vincent's Hospital, Fitzroy, Australia

  • University of Melbourne, Parkville, Australia

Locations

  • United States

  • Poland

  • Italy

  • Australia

  • New Zealand

  • Czech Republic

  • Sweden

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

  • Rituximab

  • BGB-3111

Outcome

  • N/A

Study Design

  • Open Label

  • Multinational

  • Multicenteric

  • Cohort

Phase

  • III

Study Id's

  • NCT03336333

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved